Borad, Mitesh J <br/><br/>
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.  [electronic resource] 

 -  PLoS genetics  Feb 2014 
 - e1004135 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1553-7404 
<br/><br/><label>Standard No.: </label>10.1371/journal.pgen.1004135  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Bile Duct Neoplasms--drug therapy<br/>Bile Ducts, Intrahepatic--pathology<br/>Cell Line, Tumor<br/>Cholangiocarcinoma--drug therapy<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride<br/>Genome, Human<br/>Humans<br/>Imidazoles--administration & dosage<br/>Indazoles<br/>Molecular Targeted Therapy<br/>Mutation<br/>Prognosis<br/>Protein Kinase Inhibitors<br/>Pyridazines--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Quinazolines--administration & dosage<br/>Receptor, Fibroblast Growth Factor, Type 2--antagonists & inhibitors<br/>Signal Transduction--genetics<br/>Sulfonamides--administration & dosage<br/>Transcriptome